Business Context and Reporting Period
This Form 8-K, dated June 15, 2015, reports the completion of a merger between Ruthigen, Inc. (the "Company") and Pulmatrix Operating Company ("Pulmatrix Operating"). Following the merger, the Company changed its name to Pulmatrix, Inc. The transaction involved a reverse stock split of the Company's common stock (1-for-2.5) and a change in the Company's fiscal year-end from March 31 to December 31.
Key Financial Metrics and Capital Structure
The filing details significant capital raising and debt conversion activities rather than operating financial results for a specific period.
- Private Placement Proceeds: The Company raised approximately $2.6 million in a private placement of common stock at $2.75 per share. Pulmatrix Operating raised $10.0 million in a private placement of units (stock and warrants) immediately prior to the merger.
- Debt Conversion: A $4.5 million bridge loan with 5% annual interest was converted into approximately 2.8 million post-split shares of Company Common Stock, satisfying the debt obligation.
- Ownership Structure: Post-merger, former Pulmatrix Operating equity holders own approximately 81.7% of the outstanding shares, while former Ruthigen equity holders own approximately 18.3%.
- Warrants: The Pulmatrix Operating private placement included warrants to purchase approximately 3.19 million post-split shares at an exercise price of approximately $7.563 per share (post-split basis).
Material Changes Versus Prior Period
The filing represents a fundamental change in the Company's identity and capital structure rather than a period-over-period operational comparison.
- Corporate Identity: The Company was renamed from Ruthigen, Inc. to Pulmatrix, Inc.
- Capitalization: The Company executed a 1-for-2.5 reverse stock split. The share count and ownership percentages were significantly altered by the merger exchange ratio and the conversion of the bridge loan.
- Leadership: The Board of Directors was reconstituted. All legacy Ruthigen directors resigned, and seven new directors from Pulmatrix Operating were appointed. Robert W. Clarke, Ph.D., was appointed President and CEO, and David L. Hava, Ph.D., was appointed Chief Scientific Officer.
- Fiscal Year: The fiscal year-end was changed from March 31 to December 31.
Guidance, Outlook, and Management Commentary
The filing does not provide specific financial guidance, revenue forecasts, or management commentary on future operational performance. However, it outlines key contractual milestones and risks:
- Warrant Exercisability: Warrants issued in the Pulmatrix Operating private placement are not immediately exercisable. They become exercisable upon the earliest of: (i) a strategic license agreement with guaranteed consideration of at least $20 million; (ii) a capital raise of at least $20 million at a price of at least $10.00 per share (post-split); (iii) a 60-day period where the stock price exceeds $12.50 (post-split) with sufficient volume; or (iv) a change of control.
- Executive Compensation Milestones: The CEO's second stock option (1% of outstanding shares) vests fully if the Company secures $15 million in guaranteed non-dilutive funding or in-licenses a post-investigational clinical stage asset within 18 months of the merger.
- Financial Reporting: The Company will file a transition report on Form 10-KT for the period from March 31, 2015, through December 31, 2015. Pro forma financial information is expected to be filed within 71 days.
Important Facts for Investor Verification
- Verify the post-merger share count and the impact of the 1-for-2.5 reverse stock split on existing holdings.
- Confirm the terms of the $10 million private placement warrants, specifically the high exercise price ($7.563 post-split) and the specific conditions required for them to become exercisable.
- Review the employment agreements for the new CEO and CSO, noting the significant equity grants (4% and 1.85% of outstanding shares, respectively) and the performance milestones required for full vesting.
- Monitor the upcoming Form 10-KT transition report for the first consolidated financial results under the new fiscal year structure.
- Assess the dilution impact of the bridge loan conversion and the various unregistered equity issuances to advisors and consultants.